Clinical Trial Update: A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M in Healthy UK Adults [EARLY_Phase 1]

View source ↗

Summary

This document describes an early-phase Phase Ia trial to assess safety and immunogenicity of the RH5.1 and R78C malaria vaccine candidates formulated with the M…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria Falciparum

Drugs mentioned

• Matrix-M (Matrix-M adjuvant)
• R78C (R78C malaria antigen)
• RH5.1 (RH5.1 malaria antigen)

Snippet

Sponsor: University of Oxford | Conditions: Malaria, Falciparum | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING